Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz.
Piketty
C
C
Race
E
E
Castiel
P
P
Belec
L
L
Peytavin
G
G
Si-Mohamed
A
A
Gonzalez-Canali
G
G
Weiss
L
L
Clavel
F
F
Kazatchkine
M D
MD
D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D048588:Benzoxazines; D002986:Clinical Trials as Topic; D003521:Cyclopropanes; D004352:Drug Resistance, Microbial / Q000235:genetics*; D004359:Drug Therapy, Combination; D006678:HIV / Q000187:drug effects* / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D010078:Oxazines / Q000627:therapeutic use; D010641:Phenotype; D019438:Ritonavir / Q000627:therapeutic use; D019258:Saquinavir / Q000627:therapeutic use; D017211:Treatment Failure
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D010078:Oxazines; C098320:efavirenz; D019258:Saquinavir; D019438:Ritonavir